Common bean (phaseolus vulgaris) extract with high a-amylase inhibitory activity and low hemagglutinin activity
US11096978B2 · kind B2 · utility
0Cited by
4References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2018 |
| Grant date | Aug 24, 2021 |
| Priority date | — |
| Expiry date | Dec 21, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An improved method for making a P. vulgaris bean extract that results in an extract having high α-amylase inhibitory activity and low hemagglutinin activity. The method involves treating the beans to selectively denature the hemagglutinin. A P. vulgaris bean extract is provided, having high α-amylase inhibitory activity and low hemagglutinin activity. A treatment for diabetes or method for reducing blood glucose level is disclosed using the P. vulgaris bean extract disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.